Hide metadata

dc.date.accessioned2021-12-15T12:18:17Z
dc.date.available2021-12-15T12:18:17Z
dc.date.created2021-11-26T13:04:01Z
dc.date.issued2021
dc.identifier.citationChen, Xiangjun Badian, Reza A. Hynne, Håvard Amdal, Cecilie Delphin Herlofson, Bente Brokstad Utheim, Øygunn Aass Westgaard, Kristine Løken Fineide, Fredrik Jensen, Janicke Liaaen Utheim, Tor Paaske . Alterations in meibomian glands in patients treated with intensity-modulated radiotherapy for head and neck cancer. Scientific Reports. 2021, 11:22419, 1-7
dc.identifier.urihttp://hdl.handle.net/10852/89546
dc.description.abstractPatients undergoing intensity-modulated radiotherapy (IMRT) for head and neck cancer may have increased incidence of dry eye disease and the exact mechanism is unclear. The present study aims to assess tear film and meibomian gland (MG) features in patients who received IMRT for head and neck cancer not involving the orbital area. Twenty-seven patients (64.7 ± 9.8 years) and 30 age-matched controls (61.4 ± 11.0 years) underwent a comprehensive dry eye work-up. Compared to the control group, the patients had more lid margin abnormalities, and worse meibum quality. The MG loss, calculated as (tarsal area-MG area)/tarsal area, was higher in the patient group in both the upper (53.0 ± 12.0% vs. 35.1 ± 10.3%, p < 0.001) and lower lids (69.5 ± 12.6% vs. 48.5 ± 12.5%, p < 0.001). In the patient group, more MG loss in the lower lids correlated with worse meibum quality (r = 0.445, p = 0.029). In contrast, there was no significant difference in aqueous tear production level, measured with Schirmer test. Patients treated with IMRT for head and neck cancer seemed to have comparable lacrimal gland function to the controls despite more dry eye symptoms. However, the patients had MG functional and morphological changes, which may present a higher risk for developing dry eye disease.
dc.languageEN
dc.publisherNature Portfolio
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleAlterations in meibomian glands in patients treated with intensity-modulated radiotherapy for head and neck cancer
dc.typeJournal article
dc.creator.authorChen, Xiangjun
dc.creator.authorBadian, Reza A.
dc.creator.authorHynne, Håvard
dc.creator.authorAmdal, Cecilie Delphin
dc.creator.authorHerlofson, Bente Brokstad
dc.creator.authorUtheim, Øygunn Aass
dc.creator.authorWestgaard, Kristine Løken
dc.creator.authorFineide, Fredrik
dc.creator.authorJensen, Janicke Liaaen
dc.creator.authorUtheim, Tor Paaske
cristin.unitcode185,16,17,51
cristin.unitnameOral kirurgi og oral medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1959750
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scientific Reports&rft.volume=11:22419&rft.spage=1&rft.date=2021
dc.identifier.jtitleScientific Reports
dc.identifier.volume11
dc.identifier.doihttps://doi.org/10.1038/s41598-021-01844-9
dc.identifier.urnURN:NBN:no-92178
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2045-2322
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/89546/1/Artikkel%2B74%2BMeibomian%2Bglands%2Bbest%25C3%25A5lte.pdf
dc.type.versionPublishedVersion
cristin.articleid22419


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International